Published by mark itwired
Posted on September 28, 2021
ESOMAR-certified consulting firm Future Market Insights (FMI) in its latest report forecasts that the global branded generics market will register healthy growth at a CAGR of 5.8% between 2021 and 2031.
The swift growth of branded generics market can be attributed to the growing number of patent expiry of branded or blockbuster drugs along with increasing prevalence of chronic diseases. Rising demand for cheap medical treatments is positively impacting the demand in the market.
Branded generics are pharmaceutical drugs that have been re-released with a different brand name. They are used to treat various diseases such as diabetes, hypertension, back pain and others. These drugs occupy small but lucrative subset of the entire generic market
Since branded generics are free from patenting, companies are investing handsome amounts on this drug category. The market is set to reach a valuation of around 283.2 Bn in 2021, with top players in tier-1 accounting for 20%-25% market share.
The entry of new players, simple market authorization procedures, greater profit margin and off-invoice discounts will expand branded generics market during the forecast period.
As per the FMI’s analysis, despite the slight setback due to the pandemic, the global branded generics market registered year-on-year (Y-o-Y) growth at 4.9% CAGR during 2020-2021.
“Rising demand for branded generics across both developing and developed economies along with high penetration of pharmaceutical industry will offer lucrative growth opportunities for the branded generics manufacturers during the forecast period” says the FMI analyst.
Request For Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1260
Teva, Abbott Laboratories, Novartis, Mylan, Pfizer are some prominent players operating in the branded generics market cumulatively hold around 20-25% market share.
Key players operating in branded generic market are focusing on expanding their business in emerging markets. They are adopting various organic and inorganic growth strategies such as mergers and acquisitions, advanced product development and collaborations to gain a competitive edge in the market.
In its latest report, FMI provides an incisive coverage on the global branded generics market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031.The study provides compelling insights on branded generics market on the basis of therapeutic application (oncology, cardiovascular diseases, diabetes, neurology, gastro intestinal diseases, dermatology diseases, analgesic and others), drug class (alkylating agents, anti-metabolites, hormones, anti-hypertensives, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics and others ), formulation type (oral, parenteral, topical, others) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, drug stores) across seven major regions.
Visit For Report TOC @ https://www.futuremarketinsights.com/reports/branded-generics-market/table-of-content
The branded generics market exceeded the total market value of US$ 283.2 Mn in 2021
The branded generics market exhibited steady growth at 6.5% CAGR between 2016 and 2020.
Entry of new branded generics, encouraging use of branded generics by healthcare providers and professionals and two-tiered strategy are some of the key trends driving the market.
Top prominent players of branded generics market are Teva, Abbott Laboratories, Novartis, Mylan and Pfizer
North America’s Branded Generics market demand is set to rise at 3.8% CAGR over the forecast period of 2021 and 2031.
Top players included in Tier-1 i.e., Pfizer Inc., Mylan N.V, Abbot Laboratories, Teva Pharmaceutical Industries Ltd. accounted for 20%-25% share in 2021.
The post The Branded Generics Market is poised to expand at a CAGR of 5.8% through 2031 first appeared on Market Research Blog.
ESOMAR-certified consulting firm Future Market Insights (FMI) in its latest report forecasts that the global branded generics market will register healthy growth at a CAGR of 5.8% between 2021 and 2031.
The swift growth of branded generics market can be attributed to the growing number of patent expiry of branded or blockbuster drugs along with increasing prevalence of chronic diseases. Rising demand for cheap medical treatments is positively impacting the demand in the market.
Branded generics are pharmaceutical drugs that have been re-released with a different brand name. They are used to treat various diseases such as diabetes, hypertension, back pain and others. These drugs occupy small but lucrative subset of the entire generic market
Since branded generics are free from patenting, companies are investing handsome amounts on this drug category. The market is set to reach a valuation of around 283.2 Bn in 2021, with top players in tier-1 accounting for 20%-25% market share.
The entry of new players, simple market authorization procedures, greater profit margin and off-invoice discounts will expand branded generics market during the forecast period.
As per the FMI’s analysis, despite the slight setback due to the pandemic, the global branded generics market registered year-on-year (Y-o-Y) growth at 4.9% CAGR during 2020-2021.
“Rising demand for branded generics across both developing and developed economies along with high penetration of pharmaceutical industry will offer lucrative growth opportunities for the branded generics manufacturers during the forecast period” says the FMI analyst.
Request For Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1260
Teva, Abbott Laboratories, Novartis, Mylan, Pfizer are some prominent players operating in the branded generics market cumulatively hold around 20-25% market share.
Key players operating in branded generic market are focusing on expanding their business in emerging markets. They are adopting various organic and inorganic growth strategies such as mergers and acquisitions, advanced product development and collaborations to gain a competitive edge in the market.
In its latest report, FMI provides an incisive coverage on the global branded generics market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031.The study provides compelling insights on branded generics market on the basis of therapeutic application (oncology, cardiovascular diseases, diabetes, neurology, gastro intestinal diseases, dermatology diseases, analgesic and others), drug class (alkylating agents, anti-metabolites, hormones, anti-hypertensives, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics and others ), formulation type (oral, parenteral, topical, others) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, drug stores) across seven major regions.
Visit For Report TOC @ https://www.futuremarketinsights.com/reports/branded-generics-market/table-of-content
The branded generics market exceeded the total market value of US$ 283.2 Mn in 2021
The branded generics market exhibited steady growth at 6.5% CAGR between 2016 and 2020.
Entry of new branded generics, encouraging use of branded generics by healthcare providers and professionals and two-tiered strategy are some of the key trends driving the market.
Top prominent players of branded generics market are Teva, Abbott Laboratories, Novartis, Mylan and Pfizer
North America’s Branded Generics market demand is set to rise at 3.8% CAGR over the forecast period of 2021 and 2031.
Top players included in Tier-1 i.e., Pfizer Inc., Mylan N.V, Abbot Laboratories, Teva Pharmaceutical Industries Ltd. accounted for 20%-25% share in 2021.
The post The Branded Generics Market is poised to expand at a CAGR of 5.8% through 2031 first appeared on Market Research Blog.
Explore more articles in the Research Reports category
